These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30334409)

  • 1. GLP-1, a powerful physiological incretin: an update.
    Malik J; Roohi N
    J Biol Regul Homeost Agents; 2018; 32(5):1171-1176. PubMed ID: 30334409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Incretin and bone].
    Yamada Y
    Clin Calcium; 2009 Sep; 19(9):1312-7. PubMed ID: 19721203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is GLP-1 a hormone: Whether and When?
    D'Alessio D
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):50-5. PubMed ID: 27186356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [GLP-1. Generalities and incretin-nutrient interaction].
    de la Higuera López-Frías M; Valdés Hernández S; Soriguer Escofet F
    Rev Clin Esp; 2007 Nov; 207(10):501-4. PubMed ID: 17988596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
    Lee YS; Jun HS
    Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel extrapancreatic effects of incretin.
    Yamada Y; Tsukiyama K; Sato T; Shimizu T; Fujita H; Narita T
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):76-9. PubMed ID: 27186360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity.
    Marrano N; Biondi G; Borrelli A; Cignarelli A; Perrini S; Laviola L; Giorgino F; Natalicchio A
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33671882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
    Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
    Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells.
    Moonschi FH; Hughes CB; Mussman GM; Fowlkes JL; Richards CI; Popescu I
    Acta Diabetol; 2018 May; 55(5):405-418. PubMed ID: 29264724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions.
    Girard J
    Diabetes Metab; 2008 Dec; 34(6 Pt 1):550-9. PubMed ID: 19036624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
    Yabe D; Seino Y
    Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes.
    Gautier JF; Choukem SP; Girard J
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S65-72. PubMed ID: 18640588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin-modulated beta cell energetics in intact islets of Langerhans.
    Hodson DJ; Tarasov AI; Gimeno Brias S; Mitchell RK; Johnston NR; Haghollahi S; Cane MC; Bugliani M; Marchetti P; Bosco D; Johnson PR; Hughes SJ; Rutter GA
    Mol Endocrinol; 2014 Jun; 28(6):860-71. PubMed ID: 24766140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New physiological effects of the incretin hormones GLP-1 and GIP.
    Asmar M
    Dan Med Bull; 2011 Feb; 58(2):B4248. PubMed ID: 21299928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.